메뉴 건너뛰기




Volumn 39, Issue 4, 2011, Pages 267-270

Cognition and lewy body disease

Author keywords

Cognitive impairment; Dementia; Dopamine; Lewy bodies; Parkinson; Rivastigmine

Indexed keywords

AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN;

EID: 80053277992     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)

References (12)
  • 3
    • 0033875826 scopus 로고    scopus 로고
    • What contributes to quality of life in patients with Parkinson's disease?
    • DOI 10.1136/jnnp.69.3.308
    • Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69:308-12. (Pubitemid 30636233)
    • (2000) Journal of Neurology Neurosurgery and Psychiatry , vol.69 , Issue.3 , pp. 308-312
    • Schrag, A.1    Jahanshahi, M.2    Quinn, N.3
  • 5
    • 0037335814 scopus 로고    scopus 로고
    • Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study
    • DOI 10.1001/archneur.60.3.387
    • Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of Dementia in Parkinson disease. Arch Neurol. 2003;60:387-92. (Pubitemid 36314364)
    • (2003) Archives of Neurology , vol.60 , Issue.3 , pp. 387-392
    • Aarsland, D.1    Andersen, K.2    Larsen, J.P.3    Lolk, A.4    Kragh-Sorensen, P.5
  • 6
    • 34447300709 scopus 로고    scopus 로고
    • A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia
    • DOI 10.1016/S0010-9452(08)70489-1
    • Metzler-Baddeley C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex. 2007;43:583-600. (Pubitemid 47050642)
    • (2007) Cortex , vol.43 , Issue.5 , pp. 583-600
    • Metzler-Baddeley, C.1
  • 7
    • 0019123271 scopus 로고
    • Is the mesocortical dopaminergic system involved in Parkinson disease?
    • Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system Involved in Parkinson's disease? Neurology. 1980;30:1326-30. (Pubitemid 11209189)
    • (1980) Neurology , vol.30 , Issue.12 , pp. 1326-1330
    • Javoy-Agid, F.1    Agid, Y.2
  • 8
    • 0141725645 scopus 로고    scopus 로고
    • What causes mental dysfunction in Parkinson's disease?
    • DOI 10.1002/mds.10581
    • Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord. 2003;18(Suppl 3):S63-S71. (Pubitemid 37185198)
    • (2003) Movement Disorders , vol.18 , Issue.SUPPL. 6
    • Emre, M.1
  • 9
  • 10
    • 0031060220 scopus 로고    scopus 로고
    • Cognitive deficits in Parkinson's disease
    • Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol. 1997;244:2-8. (Pubitemid 26413891)
    • (1997) Journal of Neurology , vol.244 , Issue.1 , pp. 2-8
    • Dubois, B.1    Pillon, B.2
  • 12
    • 80051957021 scopus 로고    scopus 로고
    • Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psyehopharmacology
    • 0269881110387547
    • O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psyehopharmacology. J Psychopharmacol November 18, 2010 0269881110387547
    • (2010) J Psychopharmacol November , vol.18
    • O'Brien, J.T.1    Burns, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.